VanEck Pharmaceutical ETF
PPH
49 hedge funds and large institutions have $93.1M invested in VanEck Pharmaceutical ETF in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 47 → 49 (+2)
14.75% less ownership
Funds ownership: 51.64% → 36.88% (-15%)
23% less capital invested
Capital invested by funds: $122M → $93.1M (-$28.5M)
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
71% less call options, than puts
Call options by funds: $9.18M | Put options by funds: $31.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$21.2M |
| 2 |
22CM
20/20 Capital Management
Costa Mesa,
California
|
+$5.81M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$764K |
| 4 |
RFWA
RPg Family Wealth Advisory
Burlington,
Massachusetts
|
+$204K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$32M |
| 2 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
-$22.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.89M |
| 4 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$2.06M |
| 5 |
IMC Chicago
Chicago,
Illinois
|
-$1.35M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DI
51
DFPG Investments
Sandy,
Utah
| – | -$1.03M | -16,613 | Closed |
|
|
WI
52
Wintrust Investments
Chicago,
Illinois
| – | -$626K | -10,070 | Closed |
|
53
Parallax Volatility Advisers
San Francisco,
California
| – | -$357K | -5,741 | Closed |
|
|
CFGS
54
Concourse Financial Group Securities
Birmingham,
Alabama
| – | -$32K | -500 | Closed |
|
|
WCG
55
Weaver Consulting Group
Huntington Beach,
California
| – | -$1K | -17 | Closed |
|
PPH Hedge Fund Activity: Q4 2020 in Review
49 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2020, worth a combined $93.1M — down 23% from $122M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PPH positions and 6 closed out — a net gain of 2 holders — while 9 added to existing stakes and 16 trimmed.
The largest buyer was Clough Capital Partners, opening a new position worth an estimated $21.2M. The largest seller was Bank of America, cutting an estimated $32M.
- 49 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2020, up from 47 in Q3 2020.
- Funds reported $93.1M of VanEck Pharmaceutical ETF stock for Q4 2020, down 23% quarter-over-quarter.
- 8 funds opened new VanEck Pharmaceutical ETF positions in Q4 2020 and 6 closed out, a net change of +2 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2020 was Clough Capital Partners, an estimated $21.2M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2020 was Bank of America, an estimated $32M sold.
Based on aggregated 13F filings for Q4 2020.